ATE486962T1 - Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon - Google Patents

Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon

Info

Publication number
ATE486962T1
ATE486962T1 AT05737007T AT05737007T ATE486962T1 AT E486962 T1 ATE486962 T1 AT E486962T1 AT 05737007 T AT05737007 T AT 05737007T AT 05737007 T AT05737007 T AT 05737007T AT E486962 T1 ATE486962 T1 AT E486962T1
Authority
AT
Austria
Prior art keywords
protein
receptor protein
salt
screening
new ligand
Prior art date
Application number
AT05737007T
Other languages
English (en)
Inventor
Ryo Fujii
Masataka Harada
Shuji Hinuma
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE486962T1 publication Critical patent/ATE486962T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
AT05737007T 2004-04-27 2005-04-26 Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon ATE486962T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004131726 2004-04-27
PCT/JP2005/008403 WO2005103291A1 (ja) 2004-04-27 2005-04-26 Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途

Publications (1)

Publication Number Publication Date
ATE486962T1 true ATE486962T1 (de) 2010-11-15

Family

ID=35196997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05737007T ATE486962T1 (de) 2004-04-27 2005-04-26 Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon

Country Status (6)

Country Link
US (1) US7833722B2 (de)
EP (1) EP1741792B1 (de)
JP (1) JP4685767B2 (de)
AT (1) ATE486962T1 (de)
DE (1) DE602005024537D1 (de)
WO (1) WO2005103291A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
CA2741089A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
US8460862B2 (en) * 2009-03-11 2013-06-11 Marker Gene Technologies Enzyme substrates for visualizing acidic organelles
EP2567698B1 (de) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR-17-Agonisten und Screening-Assay
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ucb製藥有限公司 吡啶基及吡基-(氮)吲哚磺醯胺
EP3584244A1 (de) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituierte alkoxypyridinylindolsulfonamide
EP3983384B1 (de) 2019-06-17 2023-10-11 UCB Pharma GmbH N-(phenyl)-indol-3-sulfonamid-derivate und ähnliche verbindungen als gpr17 modulatoren zur behandlung von störungen des zns wie multiple sklerose
WO2025243044A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
GB2642355B (en) 2024-07-05 2026-07-08 Pheno Therapeutics Ltd Polymorphs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118372T3 (es) 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
GB0003902D0 (en) 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
WO2001068842A2 (en) 2000-03-14 2001-09-20 Bayer Aktiengesellschaft Regulation of human p2y-like gpcr protein
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20050118639A1 (en) 2002-02-22 2005-06-02 Takeda Chemical Industries, Ltd Method of determining ligand
US20040176344A1 (en) * 2004-04-06 2004-09-09 Rooney Roberta Nora Malone Method to treat patients with amyotrophic lateral sclerosis and the like

Also Published As

Publication number Publication date
EP1741792A4 (de) 2008-11-05
US20080248041A1 (en) 2008-10-09
WO2005103291A1 (ja) 2005-11-03
JPWO2005103291A1 (ja) 2008-03-13
EP1741792A1 (de) 2007-01-10
EP1741792B1 (de) 2010-11-03
DE602005024537D1 (de) 2010-12-16
JP4685767B2 (ja) 2011-05-18
US7833722B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
EP1479768A4 (de) Neues screening-verfahren
DE602005024537D1 (de) Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
TW200531692A (en) Aryl aniline derivatives as β2 adrenergic receptor agonists
Biron et al. Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
ATE446294T1 (de) N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
EA200600049A1 (ru) Способы получения 3 - бензазепинов
BR0207390A (pt) Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
WO2006031556A3 (en) Amidine substituted aryl aniline compounds
WO2005000875A3 (en) Compositions and methods comprising a ligand of chemerin receptor
BRPI0409562A (pt) tratamento de condições envolvendo placas amilóides
FR2888937B1 (fr) Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
EP1619499A4 (de) Neues screening-verfahren
ATE482931T1 (de) Somatostatinrezeptor-1- und/oder -4-selektive agonisten und antagonisten
EP1584925A4 (de) Neues screening-verfahren
ATE405827T1 (de) Screening-verfahren
WO2003082320A1 (fr) Nouveau procede de criblage
EP1617216A4 (de) Neues screening-verfahren
WO2004096855A3 (en) Methods utilising g-protein coupled receptor 54
DE60329931D1 (de) Fprl1-liganden und deren verwendung
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
WO2005124361A3 (en) Uses of gpr100 receptor in diabetes and obesity regulation
SE0101856D0 (sv) Galanin receptor agonist
WO2007044940A3 (en) Antibody against a peptide derived from human mutant lamin a protein and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties